Arista Wealth Management LLC Takes $1.49 Million Position in Johnson & Johnson $JNJ

Key Points

• Arista Wealth Management LLC has acquired a new position in Johnson & Johnson, purchasing 9,747 shares valued at approximately $1.49 million in the second quarter.
• Johnson & Johnson reported a quarterly revenue of $24.02 billion and earnings per share of $2.26 for the last quarter, showcasing a net margin of 27.26%.
• The company announced a quarterly dividend of $1.30 per share, with a dividend yield of 2.7%, set to be paid on December 9th to stockholders of record on November 25th.

Arista Wealth Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,747 shares of the company's stock, valued at approximately $1,489,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $218,000. GAMMA Investing LLC increased its stake in Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock worth $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Autumn Glory Partners LLC raised its holdings in Johnson & Johnson by 0.6% during the 1st quarter. Autumn Glory Partners LLC now owns 22,287 shares of the company's stock worth $3,696,000 after buying an additional 133 shares during the period. Finally, Curran Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth about $211,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.6%

JNJ opened at $193.27 on Friday. The company has a market capitalization of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The business has a 50-day moving average of $180.49 and a 200-day moving average of $164.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is currently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Stifel Nicolaus increased their target price on Johnson & Johnson from $165.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday. Royal Bank Of Canada reiterated an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a research report on Thursday, October 9th. Finally, Sanford C. Bernstein raised their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a research report on Monday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $199.59.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.